52
Participants
Start Date
February 29, 2004
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
Mt. Sinai Medical Center, New York
Albany Medical Center, Albany
Temple University, Philadelphia
University of Maryland Medical Systems, Baltimore
Johns Hopkins University, Baltimore
INOVA Fairfax Medical Center, Fairfax
University of Virginia, Charlottesville, Charlottesville
Virginia Commonwealth University, Richmond
Medical University of South Carolina, Charleston
University of Alabama at Birmingham, Birmingham
University of Cincinnati, Cincinnati
Wayne State University, Detroit
Henry Ford Hospital, Detroit
Medical College of Wisconsin, Milwaukee
Loyola University Medical Center, Maywood
St. Louis University, St Louis
Via Christi Regional Medical Center, Wichita
University of Heidelberg, Heidelberg
Baylor College of Medicine, Houston
University of Texas HSC, San Antonio, San Antonio
CR Drew Medical Center, Los Angeles
Standford Medical Center, Palo Alto
Hartford Hospital, Hartford
Foothills Medical Centre, Calgary
Newcastle General Hospital, Newcastle upon Tyne
Collaborators (1)
FDA Office of Orphan Products Development
FED
Genentech, Inc.
INDUSTRY
Johns Hopkins University
OTHER